EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
46.81 USD   -0.51%
08/04WALL STREET STOCK EXCHANGE : Still seeing the glass half full
MS
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Technology, DuPont de Nemours...
MS
08/03Craig Hallum Lowers Exact Sciences Price Target to $60 From $81, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exact Sciences Corporation
Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. It is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.

Number of employees : 6 500 people.
Sales per Business
20202021Delta
Screening815.0754.7%1 062.3160.1% +30.33%
Precision Oncology440.4929.5%561.6831.8% +27.51%
COVID-19 Testing235.8315.8%143.108.1% -39.32%
USD in Million
Sales per region
20202021Delta
United States1 413.9194.8%1 657.1793.8% +17.2%
Non-United States77.485.2%109.916.2% +41.85%
USD in Million
Managers
Name Title Age Since
Kevin Conroy Chairman, President & Chief Executive Officer 55 2014
Jeffrey Elliott Executive VP, Chief Operating & Financial Officer 43 2021
Sandra Statz Senior VP-Clinical & Regulatory Affairs - 2012
Gary Frings Chief Information Officer - 2015
Paul Limburg Co-Chief Medical Officer - 2018
Scott Johnson Senior Vice President-Assay Research & Development - 2017
Steven Shak Co-Chief Medical Officer 70 2019
Jorge A. Garces, Dr. VP-Minimal Residual Disease & Therapy Selection 49 2021
Tim Caprez Chief Compliance Counsel & Vice President - 2015
D. Coward Secretary, Chief Administrative Officer & EVP 56 -
Members of the board
Name Title Age Since
Kevin Conroy Chairman, President & Chief Executive Officer 55 2014
Katherine S. Napier Independent Director 66 2009
Daniel Joseph Levangie Independent Director 71 2010
James Edward Doyle Lead Independent Director 75 -
Kathleen Sebelius Independent Director 73 2019
Pierre Jacquet, Dr. Independent Director 54 -
Freda C. Lewis-Hall, Dr. Independent Director 66 2020
Shacey Petrovic Independent Director 47 2020
Paul J. Clancy Independent Director 59 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 176,959,543 175,387,523 99.1% 0 0.0% 99.1%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 19,180,232 10.9%
The Vanguard Group, Inc. 15,431,734 8.77%
ARK Investment Management LLC 14,971,765 8.51%
Wellington Management Co. LLP 11,125,397 6.32%
Nikko Asset Management Co., Ltd. 5,807,605 3.30%
Capital Research & Management Co. (World Investors) 5,487,009 3.12%
Nikko Asset Management Americas, Inc. 5,320,404 3.02%
SSgA Funds Management, Inc. 4,498,159 2.56%
Baillie Gifford & Co. 4,358,720 2.48%
JPMorgan Investment Management, Inc. 4,265,153 2.42%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exact Sciences Corporation